6 results on '"Ku, May Mei-Sheng"'
Search Results
2. Early detection of breast cancer rectifies inequality of breast cancer outcomes.
- Author
-
Tabár, László, Chen, Tony Hsiu-Hsi, Yen, Amy Ming-Fang, Dean, Peter B, Smith, Robert A, Jonsson, Håkan, Törnberg, Sven, Chen, Sam Li-Sheng, Chiu, Sherry Yueh-Hsia, Fann, Jean Ching-Yuan, Ku, May Mei-Sheng, Wu, Wendy Yi-Ying, Hsu, Chen-Yang, Chen, Yu-Ching, Svane, Gunilla, Azavedo, Edward, Grundström, Helene, Sundén, Per, Leifland, Karin, and Frodis, Ewa
- Subjects
SURVIVAL ,CONFIDENCE intervals ,EARLY detection of cancer ,MAMMOGRAMS ,REGRESSION analysis ,TREATMENT effectiveness ,COMPARATIVE studies ,KAPLAN-Meier estimator ,DESCRIPTIVE statistics ,BREAST tumors - Abstract
Objectives: To explain apparent differences among mammography screening services in Sweden using individual data on participation in screening and with breast cancer–specific survival as an outcome. Methods: We analysed breast cancer survival data from the Swedish Cancer Register on breast cancer cases from nine Swedish counties diagnosed in women eligible for screening. Data were available on 38,278 breast cancers diagnosed and 4312 breast cancer deaths. Survival to death from breast cancer was estimated using the Kaplan–Meier estimate, for all cases in each county, and separately for cases of women participating and not participating in their last invitation to screening. Formal statistical comparisons of survival were made using proportional hazards regression. Results: All counties showed a reduction in the hazard of breast cancer death with participation in screening, but the reductions for individual counties varied substantially, ranging from 51% (95% confidence interval 46–55%) to 81% (95% confidence interval 74–85%). Survival rates in nonparticipating women ranged from 53% (95% confidence interval 40–65%) to 74% (95% confidence interval 72–77%), while the corresponding survival in women participating in screening varied from 80% (95% confidence interval 77–84%) to 86% (95% confidence interval 83–88%), a considerably narrower range. Conclusions: Differences among counties in the effect of screening on breast cancer outcomes were mainly due to variation in survival in women not participating in screening. Screening conferred similarly high survival rates in all counties. This indicates that the performance of screening services was similar across counties and that detection and treatment of breast cancer in early-stage reduces inequalities in breast cancer outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
3. Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women.
- Author
-
Duffy, Stephen W., Tabár, László, Yen, Amy Ming‐Fang, Dean, Peter B., Smith, Robert A., Jonsson, Håkan, Törnberg, Sven, Chen, Sam Li‐Sheng, Chiu, Sherry Yueh‐Hsia, Fann, Jean Ching‐Yuan, Ku, May Mei‐Sheng, Wu, Wendy Yi‐Ying, Hsu, Chen‐Yang, Chen, Yu‐Ching, Svane, Gunilla, Azavedo, Edward, Grundström, Helene, Sundén, Per, Leifland, Karin, and Frodis, Ewa
- Subjects
BREAST cancer ,MAMMOGRAMS ,CANCER diagnosis ,POISSON regression ,EARLY detection of cancer ,CAUSES of death ,RESEARCH ,CONFIDENCE intervals ,PATIENT participation ,MORTALITY ,TIME ,RESEARCH methodology ,MEDICAL screening ,DISEASE incidence ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,RESEARCH funding ,BREAST tumors - Abstract
Background: It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death.Methods: Among 549,091 women, covering approximately 30% of the Swedish screening-eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression.Results: Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51-0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66-0.84 [P < .001]).Conclusions: Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
4. Imaging Biomarkers as Predictors for Breast Cancer Death.
- Author
-
Wu, Wendy Yi-Ying, Tabar, Laszlo, Tot, Tibor, Fann, Ching-Yuan, Yen, Amy Ming-Fang, Chen, Sam Li-Sheng, Chiu, Sherry Yueh-Hsia, Ku, May Mei-Sheng, Hsu, Chen-Yang, Beckmann, Kerri R., Smith, Robert A., Duffy, Stephen W., and Chen, Hsiu-Hsi
- Subjects
BREAST cancer ,TUMOR markers ,BREAST cancer patients ,BIOMARKERS ,DEATH - Abstract
Background. To differentiate the risk of breast cancer death in a longitudinal cohort using imaging biomarkers of tumor extent and biology, specifically, the mammographic appearance, basal phenotype, histologic tumor distribution, and conventional tumor attributes. Methods. Using a prospective cohort study design, 498 invasive breast cancer patients diagnosed between 1996 and 1998 were used as the test cohort to assess the independent effects of the imaging biomarkers and other predictors on the risk of breast cancer death. External validation was performed with a cohort of 848 patients diagnosed between 2006 and 2010. Results. Mammographic tumor appearance was an independent predictor of risk of breast cancer death (P=0.0003) when conventional tumor attributes and treatment modalities were controlled. The casting type calcifications and architectural distortion were associated with 3.13-fold and 3.19-fold risks of breast cancer death, respectively. The basal phenotype independently conferred a 2.68-fold risk compared with nonbasal phenotype. The observed deaths did not differ significantly from expected deaths in the validation cohort. The application of imaging biomarkers together with other predictors classified twelve categories of risk for breast cancer death. Conclusion. Combining imaging biomarkers such as the mammographic appearance of the tumor with the histopathologic distribution and basal phenotype, accurately predicted long-term risk of breast cancer death. The information may be relevant for determining the need for molecular testing, planning treatment, and determining the most appropriate clinical surveillance schedule for breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
5. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.
- Author
-
Tabár, László, Dean, Peter B., Chen, Tony Hsiu-Hsi, Yen, Amy Ming-Fang, Chen, Sam Li-Sheng, Fann, Jean Ching-Yuan, Chiu, Sherry Yueh-Hsia, Ku, May Mei-Sheng, Wu, Wendy Yi-Ying, Hsu, Chen-Yang, Chen, Yu-Ching, Beckmann, Kerri, Smith, Robert A., and Duffy, Stephen W.
- Subjects
BREAST cancer ,MAMMOGRAMS ,MEDICAL needs assessment ,HIV-positive women ,BREAST cancer treatment ,WOMEN - Abstract
Background: Women and their health care providers need a reliable answer to this important question: If a woman chooses to participate in regular mammography screening, then how much will this choice improve her chances of avoiding a death from breast cancer compared with women who choose not to participate?Methods: To answer this question, we used comprehensive registries for population, screening history, breast cancer incidence, and disease-specific death data in a defined population in Dalarna County, Sweden. The annual incidence of breast cancer was calculated along with the annual incidence of breast cancers that were fatal within 10 and within 11 to 20 years of diagnosis among women aged 40 to 69 years who either did or did not participate in mammography screening during a 39-year period (1977-2015). For an additional comparison, corresponding data are presented from 19 years of the prescreening period (1958-1976). All patients received stage-specific therapy according to the latest national guidelines, irrespective of the mode of detection.Results: The benefit for women who chose to participate in an organized breast cancer screening program was a 60% lower risk of dying from breast cancer within 10 years after diagnosis (relative risk, 0.40; 95% confidence interval, 0.34-0.48) and a 47% lower risk of dying from breast cancer within 20 years after diagnosis (relative risk, 0.53; 95% confidence interval, 0.44-0.63) compared with the corresponding risks for nonparticipants.Conclusions: Although all patients with breast cancer stand to benefit from advances in breast cancer therapy, the current results demonstrate that women who have participated in mammography screening obtain a significantly greater benefit from the therapy available at the time of diagnosis than do those who have not participated. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
6. Imaging biomarkers of breast cancers originating from the major lactiferous ducts: Ductal adenocarcinoma of the breast, DAB.
- Author
-
Tabár, László, Dean, Peter B., Lee Tucker, F., Chen, Tony Hsiu-Hsi, Smith, Robert A., Duffy, Stephen W., Chiu, Sherry Yueh-Hsia, Ku, May Mei-Sheng, Fan, Chiao-Yun, and Yen, Amy Ming-Fang
- Subjects
- *
BREAST cancer , *BREAST imaging , *MAGNETIC resonance imaging , *TUMOR markers , *ADENOCARCINOMA - Abstract
Purpose: As we have previously demonstrated, breast cancers originating in the major lactiferous ducts and propagating through the process of neoductgenesis are a distinct subtype of invasive breast cancers, although by current practice they are placed within the group termed ductal carcinoma in situ (DCIS) and are consequently underdiagnosed and undertreated. Imaging biomarkers provide a reliable indication of the site of origin of this breast cancer subtype (Ductal Adenocarcinoma of the breast, DAB) and have excellent concordance with long-term patient outcome. In the present paper, the imaging biomarkers of DAB are described in detail to encourage and facilitate its recognition as a distinct, invasive breast cancer subtype.Methods: Correlation of breast imaging biomarkers with the corresponding histopathological findings using large format technology, with additional evidence from subgross, thick section histopathology to demonstrate the complex three-dimensional structure of the newly formed duct-like structures, neoducts.Results: There are six imaging biomarkers (mammographic tumour features) of DAB. Four subgroups have characteristic malignant-type calcifications on the mammogram. Two of these are characterized by intraluminal necrosis producing fragmented or dotted casting type calcifications on the mammogram; another two subgroups are characterized by intraductal fluid production which may eventually calcify, producing skipping stone-like or string of pearl-like calcifications. A fifth DAB subgroup presents with bloody or serous nipple discharge and is usually occult on mammography but is detectable with galactography and magnetic resonance imaging (MRI). The sixth subgroup presents as architectural distortion on the mammogram without associated calcifications.Conclusions: Radiologists can use these well-defined imaging biomarkers to readily detect Ductal Adenocarcinoma of the Breast, DAB. Immunochemical biomarkers are generally not determined from the DAB itself, due to the erroneous assumption that DAB is non-invasive. MRI plays a crucial role in determining disease extent and guiding surgical management. The accumulating evidence that this disease subtype is, in fact, an invasive cancer, necessitates an urgent re-evaluation of the diagnostic and management criteria for this poorly understood malignancy. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.